• Profile
Close

Mortality of patients with metastatic colorectal cancer randomized to systemic treatment vs primary tumor resection

JAMA Dec 14, 2021

van der Kruijssen DEW, Elias SG, Vink GR, et al. - In the treatment of metastatic colorectal cancer (mCRC), exercising caution is advised while considering primary tumor resection (PTR) in cases with preoperative increased serum lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, and/or neutrophil levels.

  • In this randomized phase 3 trial (CAIRO4), patients with mCRC were randomized to systemic treatment only (n=99) or PTR followed by systemic treatment (n=97) with palliative intent.

  • In the systemic treatment arm vs the PTR arm, 60-day mortality was 3% vs 11%, respectively.

  • In patients who received systemic treatment, the 60-day mortality was significantly lower than those randomized to surgery.

  • Within the surgery arm, those with increased levels of serum lactate dehydrogenase, aspartate aminotransferase, alanine aminotransferase, neutrophils, and/or right-sided tumor were found to have the highest 60-day mortality.

Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay